MedTrace Logo

VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination

NCT04403139 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-05-05

No results posted yet for this study

Summary

To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating T-cells

Conditions

  • Varicella Zoster Virus Infection

Interventions

DRUG

Shingrix

All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.

Sponsors & Collaborators

Principal Investigators

  • Christine M Johnston, MD, MPH · University of Washington

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-27
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04403139 on ClinicalTrials.gov